Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART-meso in Mesothelin-Expressing Breast Cancer
NCT05623488Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Feb 2023
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART-meso cells in triple-negative breast cancer (TNBC) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Occurrence of treatment-limiting toxicities at 90 days and Incidence of Treatment-Emergent Adverse Events at 15 years. Started Feb 2023; status: terminated.
02
Drugs
huCART-meso cells
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05623488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623488.